Pharmacists in Jarrettsville, MD Accepting Medicare

5 Pharmacists found. Showing 1 - 5

Mrs. Gina Moltz, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3714 Norrisville Rd, Jarrettsville, MD 21084 Phone: 410-557-7717    Fax: 410-557-4336

Dr. Lauren Marie Mcginnis Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3714 Norrisville Rd, Jarrettsville, MD 21084 Phone: 410-557-7717    Fax: 410-557-4336

Mrs. Elizabeth Jane Burgess, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3714 Norrisville Rd, Jarrettsville, MD 21084 Phone: 410-557-7717    Fax: 410-557-4336

Capri Joyce Digiovanni, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3714 Norrisville Rd, Jarrettsville, MD 21084 Phone: 410-557-7717    Fax: 410-557-4336

Mark H Lapouraille, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3714 Norrisville Rd, Jarrettsville, MD 21084 Phone: 410-557-7717    Fax: 410-557-4336

News Archive

Scientific data confirms therapeutic potential of Anavex's S1R agonist against Parkinson's disease

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, other diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research study published in the current issue of peer-reviewed scientific journal Brain.

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Identifying the genetic malfunction that causes these disorders raises the hope that researchers may be able to devise a targeted therapy, just as they have done for chronic myelogenous leukemia (CML), which is presently treated with Gleevec. The three leukemias that share a common genetic cause are polycythemia vera (PV), essential thrombocythemia (ET) and myeloid metaplasia with myelofibrosis (MMM).

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

Innovative health care information technology solutions to improve quality of patient care

Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), provided the integrated solution to help Methodist reduce the length of stay associated with patients and help realize gains in efficiency and revenue.

Read more Medical News

› Verified 8 days ago